2. Search Result
Search Result
Results for "

nu/nu.

" in MedChemExpress (MCE) Product Catalog:

40

Inhibitors & Agonists

1

Recombinant Proteins

3

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-11006
    KU-57788
    Maximum Cited Publications
    42 Publications Verification

    nu7441

    		 DNA-PK Cancer
    KU-57788 (NU7441) is a highly potent and selective DNA-PK inhibitor with an IC50 of 14 nM. KU-57788 is an NHEJ pathway inhibitor. KU-57788 also inhibits PI3K and mTOR with IC50s of 5.0 and 1.7 μM, respectively .
    KU-57788
  • HY-110127
    NU9056
    5+ Cited Publications

    		 Histone Acetyltransferase Apoptosis Cancer
    NU9056 is a potent and selective Tip60 (KAT5) histone acetyltransferase inhibitor with an of 2 µM. NU9056 shows >16-fold selectivity for Tip60 over PCAF, p300 and GCN5. NU9056 induces apoptosis of prostate cancer cells .
    NU9056
  • HY-18930
    NU6300

    		CDK Cancer
    NU6300 is a covalent, irreversible and ATP-competitive CDK2 inhibitor with an IC50 value of 0.16 μM. NU6300 can be used for the research of eukaryotic cell cycle- and transcription-related .
    NU6300
  • HY-15719
    NU 7026
    10+ Cited Publications

    LY293646

    		 DNA-PK Apoptosis Cancer
    NU 7026 (LY293646) is a novel specific DNA-PK inhibitor with IC50 of 0.23 μM, also inhibits PI3K with IC50 of 13 μM.
    NU 7026
  • HY-15569
    NU6102

    		CDK Cancer
    NU6102 is a potent CDK1 and CDK2 inhibitor with IC50s of 9.5 nM and 5.4 nM for CDK1/cyclinB and CDK2/cyclinA3, respectively. NU6102 shows selectivity for CDK1/CDK2 over CDK4 (IC50 of 1.6 μM), DYRK1A (IC50 of 0.9 μM), PDK1 (IC50 of 0.8 μM) and ROCKII (IC50 of 0.6 μM) .
    NU6102
  • HY-151886
    NU223612

    		PROTACs Indoleamine 2,3-Dioxygenase (IDO) Neurological Disease Cancer
    NU223612 is a potent PROTAC (PROTACs) that degrades indoleamine 2,3-dioxygenase 1 (IDO1) (Indoleamine 2,3-Dioxygenase (IDO)) with a Kd of 640 nM. NU223612 potently degrades the IDO1 protein through CRBN-mediated proteasomal degradation. NU223612 is bound to CRBN with an affinity of 290 nM. NU223612 can cross the blood-brain barrier (BBB) .
    NU223612
  • HY-15044
    NU1025

    		PARP Neurological Disease Cancer
    NU1025 is a potent PARP inhibitor with an IC50 of 400 nM and a Ki of 48 nM. NU1025 potentiates the cytotoxicity of ionizing radiation and anticancer agents. NU1025 has anti-cancer and neuroprotective activity .
    NU1025
  • HY-107419
    NU6140
    1 Publications Verification

    		 CDK Aurora Kinase Cancer
    NU6140 is a selective CDK2-cyclin A inhibitor (IC50, 0.41 μM), exhibits 10- to 36-fold selectivity over other CDKs . NU6140 also potently inhibits Aurora A and Aurora B, with IC50s of 67 and 35 nM, respectively . Enhances the apoptotic effect, with anti-cancer activity .
    NU6140
  • HY-168529
    NU074381b

    		Myosin Cancer
    NU074381b (compound 5b) is a potent S100A4 inhibitor. NU074381b inhibits S100A4-NMII complex formation with an IC50 value of 0.48 µM. NU074381b inhibits cell proliferation and migration .
    NU074381b
  • HY-13816
    NU6027

    		CDK ATM/ATR Cancer
    NU6027 is a potent and ATP-competitive inhibitor of both CDK1 and CDK2, with Kis of 2.5 μM and 1.3 μM, respectively. NU6027 is also a potent inhibitor of ATR and enhances hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner .
    NU6027
  • HY-173066
    NU227326

    		PROTACs Indoleamine 2,3-Dioxygenase (IDO) Cancer
    NU227326 is a blood-brain barrier penetrant IDO1 PROTAC degrader, with a DC50 of 4.5 nM in HiBiT degradation assays. NU227326 degrades IDO1 in U87 and GBM43 cells, with DC50 values of 7.1 nM and 11.8 nM, respectively (WB assays). NU227326 is applicable to research related to glioblastoma, prostate cancer, triple-negative breast cancer, pancreatic cancer, and ovarian cancer .
    NU227326
  • HY-19316
    NU2058

    O6-(Cyclohexylmethyl)guanine

    		 CDK Cancer
    NU2058 (O6-(Cyclohexylmethyl)guanine) is a potent, competitive and guanine-based CDK inhibitor with IC50s of 17 μM and 26 μM for CDK2 and CDK1. NU2058 has anti-cancer activity.
    NU2058
  • HY-125372
    2-Amino benzamidoxime

    ABAO

    		 Biochemical Assay Reagents Others
    2-Amino benzamidoxime (ABAO) acts as a bioconjugation reagent precursor and a fluorescent probe precursor. 2-Amino benzamidoxime contains an aniline group for imine activation of aldehydes, as well as a nucleophilic group (Nu:) located at the ortho position of the amine, which is responsible for intramolecular cyclization. 2-Amino benzamidoxime reacts with glyoxal at the N-terminus of phage-displayed peptide libraries. Derivatives of 2-Amino benzamidoxime can be used for protein bioconjugation. Derivatives of 2-Amino benzamidoxime serve as fluorescent probes .\n
    2-Amino benzamidoxime
  • HY-A0149
    Phenindamine

    nu 1504

    		 Histamine Receptor Neurological Disease
    Phenindamine (Nu 1504) is an antihistamine .
    Phenindamine
  • HY-145427
    NU5455

    		DNA-PK Cancer
    NU5455 is a potent, selective, and orally active inhibitor of DNA-PKcs. NU5455 administration increases both the efficacy and the toxicity of a parenterally administered topoisomerase inhibitor. NU5455 enhances the activity of Doxorubicin released locally in liver tumor xenografts without inducing any adverse effect .
    NU5455
  • HY-164575
    NH2-NODAGA

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    NH2-NODAGA is a NODAGA-type metal chelator that can bind to radionuclides to prepare radionuclide conjugates (RDCs). NH2-NODAGA can react with diethyl squarate in 0.5M phosphate buffer to obtain NODAGA.SA. NODAGA.SA can target L-lysine urea-L-glutamate (KuE), which is a key structure of prostate-specific membrane antigen (PSMA). NODAGA.SA.KuE can bind [68]Ga and can be used for PET examination of NMRInu/nu nude mice bearing LNCaP tumors.
    NH2-NODAGA
  • HY-15570
    NU6301

    		CDK Cancer
    NU6301 is a NU6102 (a CDK2 inhibitor) (HY-15569) prodrug. NU6301 can rapidly generate NU6102 in mouse plasma. NU6301 has anticancer activity against endometrial cancer .
    NU6301
  • HY-14206
    NU 1085

    		PARP Cancer
    NU 1085 is a potent poly(ADP-ribose) polymerase (PARP) inhibitor with a Ki of 6 nM. NU 1085 shows strong cytotoxicity to cancer cells (LC50 = 83-94 μM) and can enhance the anticancer effect of Temozolomide (HY-17364). NU 1085 can be used for the research of cancer, such as lung cancer .
    NU 1085
  • HY-122038
    NU-8165

    		MDM-2/p53 Cancer
    NU-8165 is an inhibitor of the MDM2-p53 protein-protein interaction with anti-tumor activity. Optimization of NU-8165 was guided by MDM2 NMR titrations, which indicated key binding interaction regions. NU-8165 activated MDM2 and p21 transcription in cell-based assays and showed modest selectivity for wild-type p53 cell lines .
    NU-8165
  • HY-116621
    NU-7163

    		DNA-PK Cancer
    NU-7163 is an ATP-competitive DNA-PK inhibitor (IC50=0.19 μM; Ki=24 nM). NU-7163 enhances the cytotoxicity of ionizing radiation against the HeLa human tumor cell line in vitro .
    NU-7163
  • HY-118379
    NU/ICRF 500

    		Topoisomerase Inflammation/Immunology
    NU/ICRF 500 is a topo II catalytic inhibitor which increases CREST negative micronuclei in human lymphocytes .
    NU/ICRF 500
  • HY-174352
    TERT ligand-1

    		Ligands for Target Protein for PROTAC Telomerase Cancer
    TERT ligand-1 is a PROTAC target protein ligand that can be used to synthesize the PROTAC NU-PRO-1 (HY-174351). NU-PRO-1 induces TERT degradation in cancer cells .
    TERT ligand-1
  • HY-100569
    NU-3

    Bisphosphocin nu-3

    		 Bacterial Infection
    NU-3 (Bisphosphocin NU-3) is a Bisphosphocin compound and antibacterial agent. NU-3 causes DNA condensation and cell wall deformation. NU-3 can be used in studies of Escherichia coli and Pseudomonas aeruginosa infections .
    NU-3
  • HY-122176
    NU-7107

    		Drug Derivative DNA-PK Cancer
    NU-7107 is a derivative of NU7026 (HY-15719) and a DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 >10 μM. NU-7107 is applicable for cancer research .
    NU-7107
  • HY-123118
    NU-7031

    		DNA-PK Cancer
    NU-7031 (compound 10), a coumarin derivative, is a DNA-PK inhibitor with an IC50 of 1.7 μM. NU-7031 can be used for the study of cancer .
    NU-7031
  • HY-W543341
    NU-1003

    		MOFs Others
    NU-1003 is a metal-organic framework (MOF).
    NU-1003
  • HY-W249581
    NU 1000

    		MOFs Others
    NU 1000 is a metal-organic framework (MOF).
    NU 1000
  • HY-119014
    NU-8231

    		MDM-2/p53 E1/E2/E3 Enzyme Cancer
    NU-8231 (Compound 2) is a p53-MDM2 binding inhibitor with an IC50 of 5.3-200 μM for inhibiting the p53-MDM2 interaction. NU-8231 is applicable for cancer research .
    NU-8231
  • HY-123165
    NU7200

    		Drug Metabolite DNA-PK Metabolic Disease
    NU7200 is a metabolite of the DNA-PK inhibitor NU7026 (HY-15719) .
    NU7200
  • HY-129425
    NU1064 dihydrochloride

    		PARP Others
    NU1064 (dihydrochloride) is an inhibitor of PARP. NU1064 (dihydrochloride) potentiates the cytotoxicity of DNA-methylating agent (MTIC) in a concentration-dependent manner .
    NU1064 dihydrochloride
  • HY-182605
    NU6310

    		CDK Cancer
    NU6310 is a non-covalent, ATP-competitive CDK2 inhibitor with an IC50 of 0.16 μM against CDK2. NU6310 can be used for research on cell cycle regulation related to tumors .
    NU6310
  • HY-107419R
    NU6140 (Standard)

    		Reference Standards CDK Aurora Kinase Cancer
    NU6140 (Standard) is the analytical standard of NU6140 (HY-107419). This product is intended for research and analytical applications. NU6140 is a selective CDK2-cyclin A inhibitor (IC50, 0.41 μM), exhibits 10- to 36-fold selectivity over other CDKs . NU6140 also potently inhibits Aurora A and Aurora B, with IC50s of 67 and 35 nM, respectively . Enhances the apoptotic effect, with anti-cancer activity .
    NU6140 (Standard)
  • HY-173067
    IDO1 ligand-1

    		Ligands for Target Protein for PROTAC Indoleamine 2,3-Dioxygenase (IDO) Others
    IDO1 ligand-1 is the target protein ligand of PROTAC NU227326 (HY-173066). NU227326 can be used to degrade IDO1 .
    IDO1 ligand-1
  • HY-173068
    2-(4-(Piperazin-1-yl)piperidin-1-yl)acetic acid

    		PROTAC Linkers Cancer
    2-(4-(Piperazin-1-yl)piperidin-1-yl)acetic acid is the linker that can be used for synthesis of PROTAC degrader NU227326 (HY-173066) .
    2-(4-(Piperazin-1-yl)piperidin-1-yl)acetic acid
  • HY-123237
    KRC-108

    		c-Met/HGFR FLT3 Trk Receptor Apoptosis Autophagy Cancer
    KRC-108, an aminopyridine, is an orally active multiple kinase inhibitor with IC50s of 80 nM, 23 nM, 3 nM, 70 nM, 30 nM, 39 nM for c-Met, c-Met M1250T, c-Met Y1230D, Ron, Flt3 and TrkA, respectively. KRC-108 induces cell cycle arrest, apoptotic cell death, and autophagy. KRC-108 exhibits anti-tumor activity in vivo in HT29 colorectal cancer, NCI-H441 lung cancer xenograft models in athymic BALB/c nu/nu mice .
    KRC-108
  • HY-173069
    E3 Ligase Ligand-linker Conjugate 169

    		E3 Ligase Ligand-Linker Conjugates Cancer
    E3 Ligase Ligand-linker Conjugate 169 is the conjugate composed of an E3 ligase ligand for Cereblon and a linker that can be used for synthesis of PROTAC degrader NU227326 (HY-173066) .
    E3 Ligase Ligand-linker Conjugate 169
  • HY-W1130459
    (R)-C12-200

    		Liposome Cancer
    (R)-C12-200 is the (R)-isomer of C12-200 (HY-145405), an ionizable cationic lipid and helper lipid. (R)-C12-200 enables functional mRNA delivery to head and neck squamous cell carcinoma xenograft tumor cells in NU/J immunocompromised mice, with minimal off-target delivery to liver or spleen. (R)-C12-200 can be utilized in the formation of lipid nanoparticles and mRNA delivery .
    (R)-C12-200
  • HY-164575B
    NH2-NODAGA hydrochloride

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    NH2-NODAGA hydrochloride is a NODAGA-type metal chelator that can bind to radionuclides to prepare radionuclide conjugates (RDCs). NH2-NODAGA hydrochloride can react with diethyl squarate in 0.5M phosphate buffer to obtain NODAGA.SA. NODAGA.SA can target L-lysine urea-L-glutamate (KuE), which is a key structure of prostate-specific membrane antigen (PSMA). NODAGA.SA.KuE can bind [68]Ga and can be used for PET examination of NMRInu/nu nude mice bearing LNCaP tumors.
    NH2-NODAGA hydrochloride
  • HY-164575A
    NH2-NODAGA TFA

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    NH2-NODAGA TFA is a NODAGA-type metal chelator that can bind to radionuclides to prepare radionuclide conjugates (RDCs). NH2-NODAGA TFA can react with diethyl squarate in 0.5M phosphate buffer to obtain NODAGA.SA. NODAGA.SA can target L-lysine urea-L-glutamate (KuE), which is a key structure of prostate-specific membrane antigen (PSMA). NODAGA.SA.KuE can bind [68]Ga and can be used for PET examination of NMRInu/nu nude mice bearing LNCaP tumors.
    NH2-NODAGA TFA
  • HY-164575C
    (S)-NH2-NODAGA hydrochloride

    		Drug Isomer Cancer
    (S)-NH2-NODAGA hydrochloride is the S isomer of NH2-NODAGA hydrochloride (HY-164575B). NH2-NODAGA hydrochloride is a NODAGA-type metal chelator that can bind to radioactive nuclides to prepare nuclide conjugates (RDC). NH2-NODAGA hydrochloride can react with diethyl fumarate in 0.5M phosphoric acid buffer to obtain NODAGA.SA. NODAGA.SA can target L-lysine urea-L-glutamic acid (KuE), and KuE is a key structure of prostate-specific membrane antigen (PSMA). NODAGA.SA.KuE can bind [68]Ga and can be used for PET examination in NMRInu/nu nude mice carrying LNCaP tumors.
    (S)-NH2-NODAGA hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: